New Heart Failure Medications: What Is Approved and What Is in Clinical Trials

Since 2020, the FDA has approved a run of new heart failure medicines, from new drug classes to the first treatments for amyloid heart failure. Here is what is new, who each medicine is for, and what comes next.

Author image

Reviewed by Nam Tran, PharmD

Published

Updated

Ten years ago, people with heart failure had a short list of medicines, and some types of heart failure had none at all. Since 2020, the FDA has approved a steady run of new heart failure medications: new classes, medicines for people just out of the hospital, and the first treatments for heart failure caused by amyloid protein. This article looks at what is genuinely new, year by year, who each newer medicine is for, one promising drug that did not make it, and what researchers are testing next.

Article preview image

For a complete overview of how heart failure is treated today, including the four core medicines doctors combine, see our heart failure treatment guide.

The Best Heart Failure Treatment Isn't Reaching Most Patients Who Need It.

Living with heart failure?

Studies are testing new medicines and devices for heart failure, usually added to the treatment you already take.

A timeline of new heart failure medicines

Article image

New heart failure medicines approved by the FDA, 2015 to 2025.

Each of these was approved after large clinical trials showed that it lowered the risk of hospitalization, death, or both. Several started life as medicines for other conditions, such as diabetes, before trials showed they protected the heart.

New medicines for specific situations

Some of the most important recent approvals are not for everyone with heart failure, but for particular groups who previously had few options.

After a hospital stay or a worsening episode

The weeks after a hospital stay for heart failure are a period of high risk. Two newer medicines were studied specifically in this group. Vericiguat (Verquvo), approved in 2021, is for people with reduced ejection fraction who were recently hospitalized or needed intravenous diuretics; it works on a different pathway, increasing a signaling molecule that helps blood vessels relax. Sotagliflozin (Inpefa), approved in May 2023, blocks both SGLT2 and SGLT1; in the SOLOIST-WHF trial of people with diabetes and worsening heart failure, it reduced cardiovascular deaths, hospitalizations, and urgent visits for heart failure by 33 percent compared with placebo.

Heart failure caused by amyloid

Transthyretin amyloid cardiomyopathy (ATTR-CM) happens when a misfolded protein builds up in the heart muscle and stiffens it. It is more common than once thought, especially in older men, and it needs its own treatment. Two kinds of medicine now exist. Stabilizers, tafamidis (2019) and acoramidis (Attruby, November 2024), hold the protein in its normal shape so it does not misfold. A silencer, vutrisiran (Amvuttra, approved for ATTR-CM in March 2025), reduces how much of the protein the liver makes in the first place. If you have heart failure with a thick heart wall, carpal tunnel syndrome, or a family history of amyloid, it is worth asking whether you have been tested.

Preserved ejection fraction

For decades, heart failure with preserved ejection fraction had no medicine proven to change its course. SGLT2 inhibitors and, in 2025, finerenone changed that; our treatment guide explains how they fit in alongside other care.

One promising drug that did not make it

Not every new heart failure medicine succeeds. Omecamtiv mecarbil was designed to help the heart muscle contract more strongly, and it reduced heart failure events modestly in a large trial. But in February 2023 the FDA declined to approve it, judging that the evidence was not strong enough to show a meaningful benefit. It is a reminder of why new medicines go through large trials before they reach patients: a drug can look promising and still fall short.

What comes next

Several new directions are being tested. Medicines that target inflammation in the heart, drugs that reduce how much aldosterone the body makes, gene-silencing and gene-editing approaches for amyloid and inherited heart muscle diseases, and longer-acting versions of existing drug classes are all in clinical trials. Weight loss medicines are another major area: in the SUMMIT trial, tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38 percent in people with preserved ejection fraction and obesity, and more studies of this kind are now recruiting.

New medicines usually reach patients through trials first. Most heart failure studies add the new medicine or a placebo on top of the treatment you already take, so no one stops the medicines proven to help.

Article preview image

Our guide explains how placebo-controlled trials work.

Placebo-Controlled Trials: Why They Are Key for Reliable Clinical Research

How a new heart failure medicine reaches you

FDA approval is only the first step. Guidelines from heart societies then decide where a new medicine fits; insurers decide whether and how they cover it, sometimes requiring prior approval; and doctors gradually build it into their practice. As a result, it can take years before a new medicine is widely used, and many people who could benefit are not yet taking it. Knowing what is new is one way to make sure you are not missing out.

Questions to ask your cardiologist about newer medicines

Bring your latest ejection fraction and your full medicine list, and ask: Am I on every medicine that is proven for my type of heart failure? Is there a newer option that suits my situation, for example after a recent hospital stay? Should I be tested for amyloid? Would any of my other conditions, such as diabetes, kidney disease, or obesity, change which medicines make sense? And are there clinical trials I might qualify for?

Article preview image

Our guide to the stages of heart failure can help you understand where you are.

How to Read Your Heart Failure Diagnosis, and Why the Numbers Can Move in Your Favor

How to find a heart failure study

AllClinicalTrials.com lists heart failure studies recruiting across the US, and you can filter by location before applying. Right now that includes a large group of studies for adults with heart failure and other heart conditions who already take medicine for their heart. The application takes about 5 minutes, and nothing is decided until you have gone through informed consent.

Frequently asked questions

What new heart failure drugs were approved in 2025? Two: vutrisiran (Amvuttra) in March 2025 for heart failure caused by transthyretin amyloid, and finerenone (Kerendia) in July 2025 for heart failure with an ejection fraction of 40% or higher.

What is Inpefa? Inpefa (sotagliflozin) is a once-daily tablet approved in May 2023 for heart failure. It blocks both SGLT1 and SGLT2 and was studied in people with worsening heart failure.

Is there a new treatment for amyloid heart failure? Yes. Besides tafamidis, acoramidis was approved in November 2024 and vutrisiran in March 2025. Stabilizers keep the protein from misfolding; vutrisiran reduces how much of it is made.

Why was omecamtiv mecarbil not approved? In February 2023 the FDA decided the trial evidence was not strong enough to show a meaningful benefit, despite a modest reduction in heart failure events.

Can a new medicine be added to my current heart failure treatment? Often, yes. Many newer medicines are designed to be added to existing treatment. Whether one suits you depends on your type of heart failure and other conditions, so it is a decision for you and your cardiologist.

Do heart failure trial participants get paid? Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.

Share this article on social media: